ARTICLE | Clinical News
Rezonic casopitant regulatory update
June 2, 2008 7:00 AM UTC
GlaxoSmithKline submitted an NDA for IV and oral formulations of Rezonic casopitant as an adjunct to prevent chemotherapy-induced nausea and vomiting (CINV) and to prevent postoperative nausea and vom...